LOGC:NSD-Contextlogic Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 6.07

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.28M

Analyst Target

USD 22.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 125.13B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 111.91B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 37.99B
ARGX argenx NV ADR

N/A

USD 33.78B
BGNE BeiGene Ltd

N/A

USD 26.57B
MRNA Moderna Inc

N/A

USD 21.07B
RPRX Royalty Pharma Plc

N/A

USD 16.63B
UTHR United Therapeutics Corporatio..

N/A

USD 16.00B
SMMT Summit Therapeutics PLC

N/A

USD 14.66B
PCVX Vaxcyte Inc

N/A

USD 14.16B

ETFs Containing LOGC

INKM SPDR® SSgA Income Alloca.. 12.28 % 0.39 %

N/A

USD 0.08B
FISR SPDR® SSGA Fixed Income .. 4.45 % 0.00 %

N/A

USD 0.32B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 193.24% 65% D 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 193.24% 65% D 83% B
Trailing 5 Years  
Capital Gain -39.30% 36% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.30% 36% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain 52.26% 80% B- 89% A-
Dividend Return 52.26% 80% B- 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 163.58% 24% F 12% F
Risk Adjusted Return 31.94% 85% B 64% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.